(Reuters) - Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions ...
Lilly said in a statement that patients could buy the Zepbound vials for $499 per month on its LillyDirect website, roughly 23% cheaper than the $650 it charges for its injector pen to insured ...
It has also commissioned a 3,600 MTPA plant for manufacturing Pen-G forward derivative 6-Amino ... the commissioning of 285 million ampoules and vials per annum fully export-oriented manufacturing ...